全球自然杀手细胞疗法市场规模、份额、趋势和成长分析报告（2026-2034年）

自然杀手细胞疗法市场规模预计将从 2025 年的 42.6 亿美元成长到 2034 年的 126.5 亿美元，2026 年至 2034 年的复合年增长率为 12.87%。

受自然杀手 (NK) 细胞在癌症免疫疗法中作用日益凸显的推动，NK 细胞疗法市场预计将迎来显着增长。随着研究人员不断揭示 NK 细胞靶向和清除癌细胞的潜力，基于 NK 细胞的治疗方法需求激增。细胞疗法的创新，包括基因修饰 NK 细胞和联合治疗的开发，正在提高这些治疗方法的疗效，使其对医疗服务提供者和患者更具吸引力。

此外，个人化医疗的日益普及也影响着NK细胞疗法市场。随着医疗服务提供者寻求根据患者个别情况制定治疗方案，对客製化NK细胞疗法的需求也在不断增长。这一趋势在骨髓恶性肿瘤和固态肿瘤尤其明显，因为个人化治疗可以改善治疗效果并减少副作用。

此外，对免疫疗法研发的日益重视正在推动NK细胞疗法市场的创新。生物製药公司、研究机构和临床中心之间的合作正在推动NK细胞技术和治疗方法的进步，确保新产品能够满足癌症患者不断变化的需求。医疗专业人员和患者对NK细胞疗法潜在益处的认识不断提高，也促进了市场扩张。总之，自然杀手细胞疗法市场预计将迎来强劲成长，其特点是技术进步、注重个人化治疗以及致力于改善癌症治疗。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

4. 全球自然杀手细胞疗法市场（依治疗方法）

• 市场分析、洞察与预测
• NK细胞标靶抗体
• NK细胞疗法

5. 全球自然杀手细胞疗法市场（按应用领域划分）

• 市场分析、洞察与预测
• 免疫增生性疾病
• 消化系统疾病
• 癌症
• 其他的

6. 全球自然杀手细胞疗法市场（以最终用户划分）

• 市场分析、洞察与预测
• 医院
• 研究中心和研究所
• 其他的

7. 全球自然杀手细胞疗法市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • NKT Therapeutics Inc
  • Nkarta Therapeutics Inc
  • Nantkwest Inc
  • Innate Pharma SA
  • Glycostem Therapeutics BV
  • Fortress Biotech
  • Fate Therapeutics
  • Celgene Corporation
  • Affimed NV
  • Ziopharm Oncology Inc

The Natural Killer Cells Therapeutics Market size is expected to reach USD 12.65 Billion in 2034 from USD 4.26 Billion (2025) growing at a CAGR of 12.87% during 2026-2034.

The natural killer (NK) cells therapeutics market is poised for significant growth, driven by the increasing recognition of the role of NK cells in cancer immunotherapy. As researchers continue to uncover the potential of NK cells in targeting and eliminating tumor cells, the demand for NK cell-based therapies is surging. Innovations in cell therapy, including the development of engineered NK cells and combination therapies, are enhancing the effectiveness of these treatments, making them more appealing to healthcare providers and patients.

Moreover, the growing emphasis on personalized medicine is influencing the NK cells therapeutics market. As healthcare providers seek to tailor treatments to individual patient profiles, the demand for customized NK cell therapies is rising. This trend is particularly relevant in the context of hematological malignancies and solid tumors, where personalized approaches can improve treatment outcomes and reduce adverse effects.

Furthermore, the increasing focus on research and development in immunotherapy is fostering innovation in the NK cells therapeutics market. Collaborations between bi opharmaceutical companies, research institutions, and clinical centers are driving advancements in NK cell technologies and treatment methodologies, ensuring that new products meet the evolving needs of cancer patients. The growing awareness of the potential benefits of NK cell therapies among healthcare professionals and patients is also contributing to market expansion. In summary, the natural killer cells therapeutics market is set for robust growth, characterized by technological advancements, a focus on personalized treatment approaches, and a commitment to improving cancer care.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutics

• NK Cell Directed Antibodies
• NK Cell Therapies

By Application

• Immunoproliferative Disorders
• Gastrointestinal Diseases
• Cancer
• Other

By End User

• Hospitals
• Research Centers & Institutes
• Other

COMPANIES PROFILED

• NKT Therapeutics Inc, Nkarta Therapeutics Inc, Nantkwest Inc, Innate Pharma SA, Glycostem Therapeutics BV, Fortress Biotech, Fate Therapeutics, Celgene Corporation, Affimed NV, Ziopharm Oncology Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET: BY THERAPEUTICS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutics
• 4.2. NK Cell Directed Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. NK Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Immunoproliferative Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Gastrointestinal Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Centers & Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapeutics
  • 7.2.2 By Application
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapeutics
  • 7.3.2 By Application
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapeutics
  • 7.4.2 By Application
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapeutics
  • 7.5.2 By Application
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapeutics
  • 7.6.2 By Application
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL NATURAL KILLER CELLS THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 NKT Therapeutics Inc
  • 9.2.2 Nkarta Therapeutics Inc
  • 9.2.3 Nantkwest Inc
  • 9.2.4 Innate Pharma S.A
  • 9.2.5 Glycostem Therapeutics BV
  • 9.2.6 Fortress Biotech
  • 9.2.7 Fate Therapeutics
  • 9.2.8 Celgene Corporation
  • 9.2.9 Affimed N.V
  • 9.2.10 Ziopharm Oncology Inc